Subscribe for the newsletter
Mobile Navigation
Subscribe for the Newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Actinium Pharmaceuticals, Inc.
Sort By
Newest First
Sign in
1 / 1
1 / 1
COVID-19 Test
100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML
Actinium Pharmaceuticals, Inc.
PR-M11-20-003
Nov 04, 2020
